Author

E. Michailidis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Immunology· 4 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 10 Approach:experimental assay· 9 Organism:human· 9 Assay:proteomics· 4 Approach:genetic perturbation / CRISPR· 3 Research Focus:cell type annotation· 2 Organism:mouse· 2 Approach:biophysical modeling· 1

Frequent Co-Authors

C. M. Rice· 9 shared W. M. Schneider· 6 shared A. Gazumyan· 5 shared D. F. Robbiani· 5 shared M. Caskey· 5 shared Z. Wang· 5 shared A. F. Stenzel· 4 shared A. W. Ashbrook· 4 shared

Activity by Year

2019-2024 · peak 10/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersMicrobiology

C. M. Rice

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist

J. Le Pen, G. Paniccia, V. Kinast, M. Moncada-Velez, A. W. Ashbrook, M. Bauer, H.- H. Hoffmann, A. Pinharanda, I. Ricardo-Lax, A. F. Stenzel, E. A. Rosado-Olivieri, K. H. Dinnon, W. C. Doyle, C. A. Freije, S.-H. Hong, , C. M. Rice

The paper identifies PLSCR1 as a host factor restricting SARS-CoV-2 entry, which recent variants have evolved to bypass, through a CRISPR screen and integration of genetic studies.

bioRxiv · Feb 16, 2024Immunology

Human hepatocyte PNPLA3 148M exacerbates rapid non-alcoholic steatohepatitis development in chimeric mice

M. Kabbani, E. Michailidis, S. Steensels, C. G. Fulmer, J. M. Luna, J. Le Pen, M. Tardelli, B. Razooky, I. Ricardo-Lax, C. Zou, B. Zeck, A. F. Stenzel, C. Quirk, L. Foquet, A. W. Ashbrook, , Y. P. de Jong

This study shows that the PNPLA3 148M variant in human hepatocytes worsens non-alcoholic steatohepatitis in chimeric mice on a hypercaloric diet.

bioRxiv · Nov 19, 2020 · PreprintPathology

Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks

W. M. Schneider, J. M. Luna, H.- H. Hoffmann, F. J. Sanchez-Rivera, A. A. Leal, A. W. Ashbrook, J. Le Pen, E. Michailidis, I. Ricardo-Lax, A. Peace, A. F. Stenzel, S. W. Lowe, M. R. MacDonald, C. M. Rice, J. T. Poirier

The paper identifies host factors required for SARS-CoV-2 and three seasonal coronaviruses using CRISPR screens, revealing shared and virus-specific dependencies.

bioRxiv · Oct 7, 2020Microbiology

Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors

H.- H. Hoffmann, W. M. Schneider, F. J. Sanchez-Rivera, J. M. Luna, A. W. Ashbrook, Y. M. Soto-Feliciano, A. A. Leal, J. Le Pen, I. Ricardo-Lax, E. Michailidis, Y. Hao, A. F. Stenzel, A. Peace, C. D. Allis, S. W. Lowe, , C. M. Rice

The paper identifies host factors critical for SARS-CoV-2 and related coronaviruses using CRISPR screens, revealing both shared and unique factors across different viruses and temperatures.

bioRxiv · Sep 11, 2020Microbiology

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, C. Viant, C. Gaebler, M. Cipolla, H.-H. Hoffman, T. Y. Oliveira, D. A. Oren, V. Ramos, L. Nogueira, E. Michailidis, D. F. Robbiani, A. Gazumyan, , M. C. Nussenzweig

This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.

bioRxiv · Sep 9, 2020 · PreprintImmunology

Development of Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine (EFdA) by Wild-Type and Nucleoside Reverse Transcriptase Inhibitor Resistant Human Immunodeficiency Virus Type 1

M. E. Cilento, E. Michailidis, T. V. Ilina, E. Nagy, H. Mitsuya, M. Parniak, P. R. Tedbury, S. G. Sarafianos

This study identifies mutations conferring resistance to EFdA in HIV-1, showing M184V as the primary determinant and A114S enhancing resistance.

bioRxiv · Sep 4, 2020Microbiology

LY6E impairs coronavirus fusion and confers immune control of viral disease

S. Pfaender, K. B. Mar, E. Michailidis, A. Kratzel, D. Hirt, P. V'kovski, W. Fan, N. Ebert, H. Stalder, H. Kleine-Weber, M. Hoffmann, H. H. Hoffmann, M. Saeed, R. Dijkman, E. Steinmann, , V. Thiel

This study identifies LY6E as an interferon-induced gene that restricts coronavirus entry and pathogenesis by inhibiting spike protein-mediated fusion and protecting immune cells.

Nature Microbiology · Jul 23, 2020Peer-reviewedMicrobiology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

bioRxiv · Jul 21, 2020Microbiology

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis, J. C. C. Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, , P. D. Bieniasz

The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.

bioRxiv · Jun 8, 2020Microbiology

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

bioRxiv · May 13, 2020Immunology

Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity

Q. Wang, E. Michailidis, Y. Yu, Z. Wang, A. M. Hurley, D. A. Oren, C. T. Mayer, A. Gazumyan, Z. Liu, Y. Zhou, T. Schoofs, K.-h. Yao, J. Nieke, J. Wu, Q. Jiang, , M. C. Nussenzweig

The paper identifies broadly neutralizing antibodies against HBV in elite neutralizers and shows that combinations of bNAbs targeting different epitopes are more effective than single bNAbs.

bioRxiv · Mar 4, 2020 · PreprintImmunology

An RNA-based system to study hepatitis B virus replication and select drug-resistance mutations

Y. Yu, W. M. Schneider, E. Michailidis, A. Acevedo, Y. Ni, P. Ambrose, C. Zou, M. Kabbani, C. Quirk, C. Jahan, X. Wu, S. Urban, A. Shlomai, Y. P. de Jong, C. M. Rice

This paper describes an RNA-based system to study HBV replication and predict drug resistance mutations.

bioRxiv · Oct 2, 2019 · PreprintMicrobiology